Cartherics is a biotechnology company focused on developing innovative cancer therapies. We work to create precisely-defined immunotherapy treatments to combat a variety of cancers. We take a multi-platform approach combining the best components of immune defences utilising gene editing and CAR technology – developing more precise and more accessible treatment options for patients. We are focused on solid tumours and disrupting the tumour microenvironment (TME) to make tumours accessible to immune destruction. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer. We’re developing new forms of solid cancer care treatment - helping patients fight cancer and take back control of their lives.